A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants For the Improvement of Skin Quality
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2/3
Status
Completed
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
135actual
Sites
6
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-18 | actual | When the study began enrolling |
| Primary completion | 2026-02-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-05 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Skin Quality Deficit
Interventions
- Device: JUVÉDERM® VOLITE™ — also filed as AGN-8015
- Other: Control
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants Achieving "Responder" Status for Evaluating Investigator's (EI) Live Assessment of Global Aesthetic Improvement in Skin Quality on the Treatment Area Using the Global Aesthetic Improvement Scale (GAIS)
measured Month 2
Number of Participants with Adverse Events (AEs)
measured Up to approximately Month 12
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed